Cargando…

Direct-acting oral anticoagulants (DOACs) in pregnancy: new insight from VigiBase(®)

We aimed to perform an analysis of individual case safety reports retrieved after the Standardized MedDRA Query “Pregnancy and neonatal topics” for which Direct-Acting Oral Anticoagulants (DOACs) were claimed as suspected/interacting drugs. Additionally, to investigate if exists a disproportion of c...

Descripción completa

Detalles Bibliográficos
Autores principales: Sessa, Maurizio, Mascolo, Annamaria, Callréus, Torbjörn, Capuano, Annalisa, Rossi, Francesco, Andersen, Morten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510783/
https://www.ncbi.nlm.nih.gov/pubmed/31076635
http://dx.doi.org/10.1038/s41598-019-43715-4
_version_ 1783417466813153280
author Sessa, Maurizio
Mascolo, Annamaria
Callréus, Torbjörn
Capuano, Annalisa
Rossi, Francesco
Andersen, Morten
author_facet Sessa, Maurizio
Mascolo, Annamaria
Callréus, Torbjörn
Capuano, Annalisa
Rossi, Francesco
Andersen, Morten
author_sort Sessa, Maurizio
collection PubMed
description We aimed to perform an analysis of individual case safety reports retrieved after the Standardized MedDRA Query “Pregnancy and neonatal topics” for which Direct-Acting Oral Anticoagulants (DOACs) were claimed as suspected/interacting drugs. Additionally, to investigate if exists a disproportion of cases reporting “Pregnancy and neonatal topics” adverse events rather than other adverse events for DOACs in comparison with all other drugs registered in VigiBase or warfarin. VigiBase, the World Health Organization (WHO)’s global database of individual case safety reports was used as data source. Forty-two cases of abortion were detected of which 18 (42.8%) had alternative causes for its occurrence. Fourteen cases reported congenital anomaly (8 cases) or low birth weight baby/fetal growth restriction (6 cases) of which 62.5% and 33.3% had at least one confounder, respectively. In the disproportionality analyses, a potential safety signal for spontaneous abortion emerged for rivaroxaban (Reporting Odds Ratio, ROR 2.70; 95% CI 1.79–4.07) and apixaban (ROR 6.76; 95% CI 2.99–15.25). However, when the same analyses were performed using only cases without alternative causes, no statistically significant associations for rivaroxaban when compared to all other drugs (ROR 1.05; 95% CI 0.54–2.02) or warfarin (ROR 0.79; 95% CI 0.47–1.32) were found. For apixaban, we found a statistically significant ROR for induced abortion when compared to all other drugs or warfarin. For the majority of cases claiming DOACs-induced teratogenic effects, spontaneous or induced abortion there was at least one alternative cause explaining the occurrence of the adverse events. For rivaroxaban, when cases without confounders were considered, no safety signals emerged. However, for apixaban, we found a potential safety signal suggesting an increased probability of reporting spontaneous/induced abortion rather than other events when compared to all other drugs or warfarin.
format Online
Article
Text
id pubmed-6510783
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-65107832019-05-23 Direct-acting oral anticoagulants (DOACs) in pregnancy: new insight from VigiBase(®) Sessa, Maurizio Mascolo, Annamaria Callréus, Torbjörn Capuano, Annalisa Rossi, Francesco Andersen, Morten Sci Rep Article We aimed to perform an analysis of individual case safety reports retrieved after the Standardized MedDRA Query “Pregnancy and neonatal topics” for which Direct-Acting Oral Anticoagulants (DOACs) were claimed as suspected/interacting drugs. Additionally, to investigate if exists a disproportion of cases reporting “Pregnancy and neonatal topics” adverse events rather than other adverse events for DOACs in comparison with all other drugs registered in VigiBase or warfarin. VigiBase, the World Health Organization (WHO)’s global database of individual case safety reports was used as data source. Forty-two cases of abortion were detected of which 18 (42.8%) had alternative causes for its occurrence. Fourteen cases reported congenital anomaly (8 cases) or low birth weight baby/fetal growth restriction (6 cases) of which 62.5% and 33.3% had at least one confounder, respectively. In the disproportionality analyses, a potential safety signal for spontaneous abortion emerged for rivaroxaban (Reporting Odds Ratio, ROR 2.70; 95% CI 1.79–4.07) and apixaban (ROR 6.76; 95% CI 2.99–15.25). However, when the same analyses were performed using only cases without alternative causes, no statistically significant associations for rivaroxaban when compared to all other drugs (ROR 1.05; 95% CI 0.54–2.02) or warfarin (ROR 0.79; 95% CI 0.47–1.32) were found. For apixaban, we found a statistically significant ROR for induced abortion when compared to all other drugs or warfarin. For the majority of cases claiming DOACs-induced teratogenic effects, spontaneous or induced abortion there was at least one alternative cause explaining the occurrence of the adverse events. For rivaroxaban, when cases without confounders were considered, no safety signals emerged. However, for apixaban, we found a potential safety signal suggesting an increased probability of reporting spontaneous/induced abortion rather than other events when compared to all other drugs or warfarin. Nature Publishing Group UK 2019-05-10 /pmc/articles/PMC6510783/ /pubmed/31076635 http://dx.doi.org/10.1038/s41598-019-43715-4 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Sessa, Maurizio
Mascolo, Annamaria
Callréus, Torbjörn
Capuano, Annalisa
Rossi, Francesco
Andersen, Morten
Direct-acting oral anticoagulants (DOACs) in pregnancy: new insight from VigiBase(®)
title Direct-acting oral anticoagulants (DOACs) in pregnancy: new insight from VigiBase(®)
title_full Direct-acting oral anticoagulants (DOACs) in pregnancy: new insight from VigiBase(®)
title_fullStr Direct-acting oral anticoagulants (DOACs) in pregnancy: new insight from VigiBase(®)
title_full_unstemmed Direct-acting oral anticoagulants (DOACs) in pregnancy: new insight from VigiBase(®)
title_short Direct-acting oral anticoagulants (DOACs) in pregnancy: new insight from VigiBase(®)
title_sort direct-acting oral anticoagulants (doacs) in pregnancy: new insight from vigibase(®)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510783/
https://www.ncbi.nlm.nih.gov/pubmed/31076635
http://dx.doi.org/10.1038/s41598-019-43715-4
work_keys_str_mv AT sessamaurizio directactingoralanticoagulantsdoacsinpregnancynewinsightfromvigibase
AT mascoloannamaria directactingoralanticoagulantsdoacsinpregnancynewinsightfromvigibase
AT callreustorbjorn directactingoralanticoagulantsdoacsinpregnancynewinsightfromvigibase
AT capuanoannalisa directactingoralanticoagulantsdoacsinpregnancynewinsightfromvigibase
AT rossifrancesco directactingoralanticoagulantsdoacsinpregnancynewinsightfromvigibase
AT andersenmorten directactingoralanticoagulantsdoacsinpregnancynewinsightfromvigibase